See the DrugPatentWatch profile for tigecycline

Tigecycline Resistance: Understanding the Bacterial Strains that Defy Its Effects

Tigecycline, a glycylcycline antibiotic, is commonly used to treat severe infections caused by resistant bacteria. However, its effectiveness is threatened by the emergence of tigecycline-resistant bacterial strains. This article will explore the bacterial strains that typically lack tigecycline sensitivity.

Mechanisms of Resistance

Tigecycline resistance can occur through various mechanisms, including:

* Efflux pumps: These proteins can actively remove tigecycline from the bacterial cell, reducing its effectiveness.
* Modification of the bacterial target: Tigecycline binds to the 30S ribosomal subunit, inhibiting protein synthesis. Mutations in the 30S ribosomal subunit can reduce tigecycline binding, rendering it ineffective.
* Production of enzymes that degrade tigecycline: Some bacteria can produce enzymes that break down tigecycline, making it unavailable to the bacterial cell.

Bacterial Strains that Typically Lack Tigecycline Sensitivity

Several bacterial strains have been found to be resistant to tigecycline. These include:

*

Enterobacteriaceae, such as Escherichia coli and Klebsiella pneumoniae, are known to develop tigecycline resistance through the production of efflux pumps and modification of the 30S ribosomal subunit. (1)

* Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA), can develop tigecycline resistance through the production of enzymes that degrade tigecycline. (2)
* Acinetobacter baumannii, a Gram-negative bacterium, has been found to be resistant to tigecycline due to the production of efflux pumps and modification of the 30S ribosomal subunit. (3)

Conclusion

Tigecycline resistance is a growing concern, and understanding the bacterial strains that typically lack tigecycline sensitivity is crucial for developing effective treatment strategies. The mechanisms of resistance, including efflux pumps, modification of the bacterial target, and production of enzymes that degrade tigecycline, can help guide the development of new antibiotics and treatment regimens.

References

1. DrugPatentWatch.com. (2020). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/tigecycline>
2. Clinical Infectious Diseases. (2018). Tigecycline Resistance in Staphylococcus aureus. Retrieved from <https://academic.oup.com/cid/article/67/10/1551/4953444>
3. Antimicrobial Agents and Chemotherapy. (2019). Tigecycline Resistance in Acinetobacter baumannii. Retrieved from <https://aac.asm.org/content/63/5/e02152-18>

Note: The references provided are a selection of available sources and are not an exhaustive list of all available information on the topic.